Article – Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery
As gene therapy continues to evolve, nonviral DNA delivery is rapidly gaining traction as a safer, more flexible alternative to traditional viral vectors. Touchlight’s groundbreaking synthetic dbDNA™ technology is at the forefront of this revolution, offering enhanced scalability, flexibility, and a superior safety profile compared to plasmid DNA (pDNA). This innovation opens up new therapeutic possibilities and paves the way for the next generation of genetic medicines.
In this article, Lisa Caproni, Ph.D., Associate Director of Applications, discusses how recent advancements in lipid nanoparticle (LNP) and electroporation technologies are unlocking the potential of nonviral gene therapies. Discover how dbDNA™ can overcome the limitations of viral vectors, allowing for re-dosable, scalable, and safer therapeutic solutions.
What You’ll Learn:
- The challenges of viral-vector-based therapies and how dbDNA™ provides a compelling alternative
- Innovations in nonviral gene delivery, including the latest breakthroughs in LNP and electroporation technologies
- Why dbDNA™ is poised to revolutionize genetic medicine with its superior scalability, safety, and efficacy
Author – Lisa Caproni, Ph.D.
Access the article here:
About doggybone DNA (dbDNA™)
Doggybone or dbDNA™ is linear, double stranded, covalently closed DNA vector which is produced in an enzymatic manufacturing process. It can incorporate a gene of interest from 600bp to >20kb making it very flexible to support a range of genetic medicines.